Eptifibatide

In plain language

Eptifibatide is a heart drug used in hospitals during heart attacks and stent procedures, sold as Integrilin (the brand is discontinued; generics remain). It stops platelets from clumping into clots.

Its design came from an unexpected source: the venom of the southeastern pygmy rattlesnake, whose bite causes uncontrolled bleeding. Scientists isolated the part of the venom protein responsible and rebuilt it as a small, stable ring of seven amino acids that blocks the platelet receptor that lets platelets stick together.

For students

Eptifibatide is a cyclic heptapeptide (about 832 Da) modeled on barbourin, a KGD-containing disintegrin from Sistrurus miliarius barbouri venom. The KGD motif confers high selectivity for platelet glycoprotein IIb/IIIa (integrin alphaIIbbeta3) over other RGD-recognizing integrins, blocking fibrinogen bridging between platelets and the final common pathway of aggregation.

Developed by Robert Scarborough and colleagues at COR Therapeutics, it was approved in 1998 for acute coronary syndromes (non-ST elevation and ST-elevation MI) and percutaneous coronary intervention, given as a bolus and infusion with aspirin and heparin. The PURSUIT trial (10,948 patients) and IMPACT-II (4,010 patients) showed significant reductions in the composite of death and MI at 30 days versus standard care. The GPIIb/IIIa inhibitor class has since contracted as P2Y12 inhibitors and radial access improved outcomes, and the Integrilin brand was discontinued, though generic eptifibatide remains available.

For researchers and instructors

Biochemistry. The disintegrin-to-drug path (venom KGD to cyclic peptidomimetic) is one of the first rational translational designs from animal toxin pharmacology, alongside captopril's snake-venom origins.

Pharmacology. Competitive, rapidly reversible (about 2-4 hour platelet function recovery) alphaIIbbeta3 blockade; dosing adjusts for renal function; bleeding is the main adverse effect, and thrombocytopenia occurs in about 1-2%.

Human evidence. PURSUIT (n=10,948, NEJM 1998) showed 1.5% absolute reduction in 30-day death or MI; IMPACT-II supportive; class-wide benefit declined in the modern era per meta-analyses and guidelines.

Teaching point. A clean venom-to-medicine story that also teaches how procedural and pharmacological advances can make an effective drug obsolete.